[144] Alnylam Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Alnylam Pharmaceuticals (ALNY) notice reports a proposed sale of 18,000 shares of common stock through UBS Financial Services on the NASDAQ, with an aggregate market value of $8,300,070.00 and 131,079,015 shares outstanding. The securities were acquired and are proposed to be sold on 09/09/2025 via exercise of stock options from the issuer, with cash payment recorded. The filer reports no securities sold in the past three months. The form includes the standard representation that the seller is not aware of undisclosed material adverse information and references Rule 10b5-1 plan adoption if applicable.

Positive

• Transaction executed through a major broker-dealer (UBS Financial Services)
• No securities sold in the past three months, as reported on the form
• Form includes seller's representation about absence of undisclosed material adverse information

Negative

• Aggregate market value is $8,300,070.00, representing a non-trivial cash amount proposed for sale
• Form lacks identification of the selling person's name or relationship in the provided extract, limiting context

Insights

Securities Analyst

TL;DR: Insider-originated sale notice for 18,000 shares worth $8.3M, executed via a major broker, appears routine and small relative to total shares outstanding.

The filing documents a single proposed sale of 18,000 common shares acquired and to be sold on the same date by exercise of stock options, with cash payment. Execution through UBS Financial Services suggests use of an established broker-dealer. The filing notes no prior sales in the last three months and includes the statutory representation about material nonpublic information. Based solely on the disclosed facts, this is a routine insider transaction notice without additional context on the seller's identity or any trading plan.

Corporate Governance Expert

TL;DR: Form 144 records a compliance disclosure for a planned sale; it includes the required seller certification and Rule 10b5-1 mention.

The notice contains the standard attestations required by Rule 144, including the seller's representation regarding material information and an explicit field for Rule 10b5-1 plan adoption or instruction date. The form indicates acquisition via option exercise and immediate planned disposition, and it reports no aggregated recent sales by the filer. From a governance and disclosure perspective, the filing meets the procedural elements presented here; no governance issues or compliance exceptions are evident from the disclosed content.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc. 11 Madison Avenue 4th Floor New York NY 10010	18000	8300070.00	131079015	09/09/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/09/2025	Exercise of stock options	Issuer			18000	09/09/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the ALNY Form 144 disclose about the proposed sale?

The filing discloses a proposed sale of 18,000 common shares via UBS on NASDAQ with an aggregate market value of $8,300,070.00 and 131,079,015 shares outstanding.

When were the shares acquired according to the ALNY Form 144?

The shares were acquired on 09/09/2025 by exercise of stock options from the issuer, with cash payment recorded the same date.

Does the Form 144 report any sales of ALNY securities in the past three months?

No. The filing states 'Nothing to Report' for securities sold during the past three months.

Through which broker will the ALNY shares be sold?

UBS Financial Services, Inc., 11 Madison Avenue, New York, NY is listed as the broker for the proposed sale.

Does the filing indicate the seller relied on a Rule 10b5-1 plan?

The form includes a field for Rule 10b5-1 plan adoption or instruction date, but no specific plan adoption date is provided in the extracted content.